Similar articles

• JSH practical guidelines for hematological malignancies, 2018: I. Leukemia-2. Acute promyelocytic leukemia (APL).

  Fujita H, Ishikawa Y, Yokoyama Y. Fujita H, et al. Int J Hematol. 2020 Jun;111(6):747-760. doi: 10.1007/s12185-020-02884-z. Epub 2020 Apr 28. Int J Hematol. 2020. PMID: 32347422 No abstract available.
• Switching from all-trans retinoic acid to arsenic trioxide for newly diagnosed acute promyelocytic leukemia.

  Imagawa J. Imagawa J. Leuk Lymphoma. 2018 Dec;59(12):3013-3015. doi: 10.1080/10428194.2018.1443333. Epub 2018 Apr 4. Leuk Lymphoma. 2018. PMID: 29616847 No abstract available.
• Bone Marrow Findings in Patients With Acute Promyelocytic Leukemia Treated With Arsenic Trioxide.

  Miller KP, Venkataraman G, Gocke CD, Batista DA, Borowitz MJ, Burns KH, Pratz K, Duffield AS. Miller KP, et al. Am J Clin Pathol. 2019 Oct 7;152(5):675-685. doi: 10.1093/ajcp/aqz087. Am J Clin Pathol. 2019. PMID: 31305869 Free PMC article.
• Does acute promyelocytic leukemia patient with the STAT5B/RARa fusion gene respond well to decitabine?: A case report and literature review.

  Wang L, Yan X, He J. Wang L, et al. Medicine (Baltimore). 2020 Oct 23;99(43):e22923. doi: 10.1097/MD.0000000000022923. Medicine (Baltimore). 2020. PMID: 33120845 Free PMC article. Review.
• Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia.

  Breccia M, Foà R. Breccia M, et al. Expert Rev Hematol. 2019 Feb;12(2):81-87. doi: 10.1080/17474086.2019.1562332. Epub 2019 Jan 7. Expert Rev Hematol. 2019. PMID: 30572725 Review.